AR048362A1 - Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos - Google Patents
Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismosInfo
- Publication number
- AR048362A1 AR048362A1 ARP050101295A ARP050101295A AR048362A1 AR 048362 A1 AR048362 A1 AR 048362A1 AR P050101295 A ARP050101295 A AR P050101295A AR P050101295 A ARP050101295 A AR P050101295A AR 048362 A1 AR048362 A1 AR 048362A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- optionally substituted
- sulfur
- oxygen
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Steroid Compounds (AREA)
Abstract
La presente se refiere a una sal farmacéuticamente aceptable del mismo, que ejerce una accion inhibitoria contra la proteína de transferencia del éster de colesterilo (CETP). Reivindicacion 1: Un compuesto caracterizado por la formula (1), en la cual R1 es un átomo de hidrogeno, un grupo alcoxicarbonilo opcionalmente sustituido, un grupo carbamoilo opcionalmente sustituido, un grupo alquilo opcionalmente sustituido, un grupo alcanoilo opcionalmente sustituido, un grupo heterocíclico monocíclico o bicíclico saturado o insaturado que contiene entre 1 y 4 heteroátomos seleccionados independientemente entre átomos de oxígeno, azufre y nitrogeno (el grupo heterocíclico es opcionalmente sustituido), o un grupo carbonilo heterocíclico monocíclico o bicíclico saturado o insaturado que contiene entre 1 y 4 heteroátomos seleccionados independientemente entre átomos de oxígeno, azufre y nitrogeno (el grupo heterocíclico es opcionalmente sustituido); R2 es un átomo de hidrogeno o un grupo opcionalmente sustituido; R3 es un átomo de hidrogeno o un grupo alquilo opcionalmente sustituido; R4 es un grupo alquileno opcionalmente sustituido; R5 es un grupo heterocíclico monocíclico o bicíclico saturado o insaturado que contiene entre 1 y 4 heteroátomos seleccionados independientemente entre átomos de oxígeno, azufre y nitrogeno, dicho grupo heterocíclico es opcionalmente sustituido; R6, R7 y R8 son independientemente un átomo de hidrogeno, un átomo halogeno, un grupo hidroxi, un grupo nitro, un grupo ciano, un grupo alquilo opcionalmente sustituido, un grupo alcoxi opcionalmente sustituido, un grupo alquil sulfonil oxi opcionalmente sustituido, un grupo mono- o di-alquilacrbamoilo opcionalmente sustituido, o un grupo amino opcionalmente sustituido; o R6, y R7, o R7 y R8 pueden combinarse en los extremos para formar un grupo alquileno, el grupo alquileno opcionalmente contiene entre 1 y 3 heteroátomos seleccionados independientemente átomos de nitrogeno, azufre y oxígeno, y pueden tener uno o más sustituyentes; y R10 es un anillo aromático que opcionalmente contiene entre 1 y 3 heteroátomos seleccionados independientemente entre átomos de oxígeno, azufre y nitrogeno (el anillo aromático está opcionalmente sustituido), o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004109551 | 2004-04-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR048362A1 true AR048362A1 (es) | 2006-04-19 |
Family
ID=35064445
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050101295A AR048362A1 (es) | 2004-04-02 | 2005-04-01 | Derivados de tetrahidronaftiridina y proceso para la preparacion de los mismos |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7781443B2 (es) |
| EP (1) | EP1732924B1 (es) |
| JP (1) | JP4633731B2 (es) |
| KR (1) | KR100874623B1 (es) |
| CN (1) | CN100441579C (es) |
| AR (1) | AR048362A1 (es) |
| AU (1) | AU2005228291B2 (es) |
| BR (1) | BRPI0509588A (es) |
| CA (1) | CA2560008C (es) |
| IL (1) | IL178194A0 (es) |
| MX (1) | MXPA06011416A (es) |
| MY (1) | MY139887A (es) |
| NO (1) | NO20065012L (es) |
| NZ (1) | NZ550267A (es) |
| RU (1) | RU2356902C2 (es) |
| TW (1) | TWI345568B (es) |
| WO (1) | WO2005095395A2 (es) |
| ZA (1) | ZA200607782B (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0508966A (pt) | 2004-03-26 | 2007-08-21 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
| US7700774B2 (en) | 2004-12-20 | 2010-04-20 | Dr. Reddy's Laboratories Ltd. | Heterocyclic compounds and their pharmaceutical compositions |
| MX2007007919A (es) | 2004-12-31 | 2008-01-22 | Reddy Us Therapeutics Inc | Nuevos derivados de bencilaminas como inhibidores de la proteina de transferencia de colesteril-ester(cetp). |
| US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
| JP4681526B2 (ja) * | 2005-09-29 | 2011-05-11 | 田辺三菱製薬株式会社 | 医薬組成物 |
| RU2008119687A (ru) | 2005-10-21 | 2009-11-27 | Новартис АГ (CH) | Комбинации органических соединений |
| US7790770B2 (en) | 2005-11-23 | 2010-09-07 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US7652023B2 (en) | 2005-11-23 | 2010-01-26 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| PE20071025A1 (es) * | 2006-01-31 | 2007-10-17 | Mitsubishi Tanabe Pharma Corp | Compuesto amina trisustituido |
| US7750019B2 (en) | 2006-08-11 | 2010-07-06 | Kowa Company, Ltd. | Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same |
| US7790737B2 (en) | 2007-03-13 | 2010-09-07 | Kowa Company, Ltd. | Substituted pyrimidine compounds and their utility as CETP inhibitors |
| CA2683534C (en) | 2007-04-13 | 2015-02-24 | Kowa Company, Ltd. | Novel pyrimidine compound having dibenzylamine structure and medicament comprising the same |
| PL2207775T3 (pl) * | 2007-11-05 | 2012-08-31 | Novartis Ag | Pochodne 4-benzyloamino-1-karboksyacylo-piperydyny jako inhibitory CETP użyteczne do leczenia chorób, takich jak hiperlipidemia lub stwardnienie tętnic |
| AU2008333272B2 (en) * | 2007-12-03 | 2012-03-29 | Novartis Ag | 1,2-disubstituted-4-benzylamino-pyrrolidine derivatives as CETP inhibitors useful for the treatment of diseases such as hyperli pidemia or arteriosclerosis |
| KR101660059B1 (ko) | 2008-08-22 | 2016-09-26 | 박스알타 인코퍼레이티드 | 중합체 벤질 카르보네이트-유도체 |
| CN102740699A (zh) * | 2009-09-04 | 2012-10-17 | 范德比尔特大学 | 用于治疗神经学上的功能失调的mglur4变构增效剂、组合物和方法 |
| DK3415515T3 (da) * | 2009-11-27 | 2020-03-16 | Adverio Pharma Gmbh | Fremgangsmåde til fremstilling af methyl-{4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamat |
| CN103415511B (zh) * | 2011-01-31 | 2016-01-20 | 国立大学法人长崎大学 | 光学活性化合物或其盐的制造方法 |
| JP5964965B2 (ja) | 2011-08-18 | 2016-08-03 | ドクター レディズ ラボラトリーズ リミテッド | コレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての置換複素環式アミン化合物 |
| IN2014CN02290A (es) | 2011-09-27 | 2015-06-19 | Reddys Lab Ltd Dr | |
| CA2860601C (en) | 2012-01-06 | 2016-07-05 | Daiichi Sankyo Company, Limited | Acid addition salt of substituted pyridine compound |
| AU2012366148B2 (en) * | 2012-01-19 | 2016-12-01 | Oncotherapy Science, Inc. | 1,5-naphthyridine derivatives and melk inhibitors containing the same |
| MX2015005949A (es) | 2012-11-16 | 2015-09-08 | Biocryst Pharm Inc | Nucleosidos que contienen aza-azucar antiviral. |
| US20200077658A1 (en) | 2016-12-16 | 2020-03-12 | Basf Se | Pesticidal Compounds |
| CA3065683A1 (en) | 2017-05-30 | 2018-12-06 | Millennium Pharmaceuticals, Inc. | Method for producing optically active compound |
| CN107245074B (zh) * | 2017-06-20 | 2019-04-09 | 牡丹江医学院附属红旗医院 | 用于治疗脑梗死的化合物及其制备方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP970330B1 (en) | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
| US6147090A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
| GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| BR0307332A (pt) | 2002-02-01 | 2004-12-07 | Pfizer Prod Inc | Formas de dosagem farmacêuticas de liberação controlada de um inibidor da proteìna de transferência do éster de colesterol |
| BRPI0508966A (pt) * | 2004-03-26 | 2007-08-21 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
-
2005
- 2005-03-30 MY MYPI20051440A patent/MY139887A/en unknown
- 2005-03-30 TW TW094109944A patent/TWI345568B/zh not_active IP Right Cessation
- 2005-04-01 AU AU2005228291A patent/AU2005228291B2/en not_active Ceased
- 2005-04-01 RU RU2006138597/04A patent/RU2356902C2/ru not_active IP Right Cessation
- 2005-04-01 MX MXPA06011416A patent/MXPA06011416A/es active IP Right Grant
- 2005-04-01 AR ARP050101295A patent/AR048362A1/es not_active Application Discontinuation
- 2005-04-01 BR BRPI0509588-3A patent/BRPI0509588A/pt not_active IP Right Cessation
- 2005-04-01 CN CNB2005800104921A patent/CN100441579C/zh not_active Expired - Fee Related
- 2005-04-01 JP JP2006534488A patent/JP4633731B2/ja not_active Expired - Fee Related
- 2005-04-01 WO PCT/JP2005/006895 patent/WO2005095395A2/en not_active Ceased
- 2005-04-01 KR KR1020067020091A patent/KR100874623B1/ko not_active Expired - Fee Related
- 2005-04-01 NZ NZ550267A patent/NZ550267A/en unknown
- 2005-04-01 CA CA2560008A patent/CA2560008C/en not_active Expired - Fee Related
- 2005-04-01 EP EP05728666A patent/EP1732924B1/en not_active Expired - Lifetime
-
2006
- 2006-09-18 ZA ZA200607782A patent/ZA200607782B/en unknown
- 2006-09-19 IL IL178194A patent/IL178194A0/en unknown
- 2006-09-27 US US11/527,556 patent/US7781443B2/en not_active Expired - Fee Related
- 2006-11-01 NO NO20065012A patent/NO20065012L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| NO20065012L (no) | 2006-12-28 |
| TWI345568B (en) | 2011-07-21 |
| JP4633731B2 (ja) | 2011-02-16 |
| ZA200607782B (en) | 2008-02-27 |
| US7781443B2 (en) | 2010-08-24 |
| CA2560008A1 (en) | 2005-10-13 |
| WO2005095395A3 (en) | 2006-06-01 |
| IL178194A0 (en) | 2006-12-31 |
| JP2007530444A (ja) | 2007-11-01 |
| RU2006138597A (ru) | 2008-05-10 |
| CN1938301A (zh) | 2007-03-28 |
| BRPI0509588A (pt) | 2007-09-25 |
| CN100441579C (zh) | 2008-12-10 |
| EP1732924A2 (en) | 2006-12-20 |
| CA2560008C (en) | 2010-06-01 |
| KR20060132966A (ko) | 2006-12-22 |
| MY139887A (en) | 2009-11-30 |
| AU2005228291B2 (en) | 2008-06-26 |
| TW200536853A (en) | 2005-11-16 |
| AU2005228291A1 (en) | 2005-10-13 |
| RU2356902C2 (ru) | 2009-05-27 |
| WO2005095395A2 (en) | 2005-10-13 |
| US20070032485A1 (en) | 2007-02-08 |
| EP1732924B1 (en) | 2012-11-28 |
| KR100874623B1 (ko) | 2008-12-17 |
| NZ550267A (en) | 2009-08-28 |
| MXPA06011416A (es) | 2006-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107377A2 (es) | Compuestos derivados de tetrahidroquinolina | |
| PE20001093A1 (es) | 3-amino-4-aril-maleimidas como inhibidores de gsk-3 | |
| CO6241101A2 (es) | Derivados de quinolina como inhibidores de la p13 quinasa | |
| AR059249A1 (es) | Compuesto amina trisustituido | |
| AR044874A1 (es) | Derivados de 4- cianopirazol-3 - carboxamida, su preparacion y su aplicacion en terapeutica | |
| AR061369A1 (es) | Derivados de pirimidina y composiciones farmaceuticas que los comprenden | |
| AR047085A1 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalina-2-il-amino)benzamida y compuestos relacionados como inhibidores de glucogeno fosforilasa para el tratamiento de diabetes y obesidad | |
| ES2328820T3 (es) | Derivados de 4-(pirazol-3-ilamino)pirimidina para uso en el tratamiento de cancer. | |
| AR043111A1 (es) | Derivados monoacilados de o-fenilendiaminas | |
| AR061567A1 (es) | Compuestos puros enantiomericamente para el tratamiento de desordenes proliferativos | |
| AR041184A1 (es) | Derivados de benzopiranonas, inhibidores de las cinasas dependientes de ciclinas y su uso | |
| AR059248A1 (es) | Heterociclos nitrogenados y sus usos como inhibidores de aterosclerosis. composiciones farmaceuticas | |
| AR035716A1 (es) | Compuestos agonistas del receptor beta3-adrenergico, uso de los mismos en la fabricacion de medicamentos y composiciones farmaceuticas conteniendo los mismos | |
| PE20200608A1 (es) | Nuevos derivados de azaquinolina | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| TW200745117A (en) | Macrocylic inhibitors of hepatitis C virus | |
| AR068538A1 (es) | Compuesto heterociclico de 5 miembros con actividad supresora de la secrecion de acido | |
| AR074109A1 (es) | Pirrolidinas heterociclicas agonistas de receptores de la melanocortina, composiciones farmaceuticas que las contienen y uso de las mismas en el tratamiento de la obesidad, diabetes y disfuncion erectil. | |
| AR083953A1 (es) | Compuestos para tratar enfermedades neurodegenerativas | |
| AR060623A1 (es) | Compuestos derivados de 2-azetidinona y un metodo de preparacion | |
| DOP2010000022A (es) | Derivados de pirimidina 934 | |
| AR054481A1 (es) | Derivados de 2-azetidinonas como inhibidores de la absorcion de colesterol | |
| AR057380A1 (es) | Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos | |
| AR066103A1 (es) | Derivados de triazolopiridin - carboxamidas, su preparacion y su aplicacion en terapeutica | |
| CO6210825A2 (es) | Derivado de heterocicliden-n-(aril)acetamina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |